Sitemap
-
- Media Releases
- EMD Serono Receives Health Canada Notice of Compliance for MAVENCLAD™ (cladribine tablets)
- Merck KGaA Darmstadt, Germany Announces Recipients of €1 Million Grant for Multiple Sclero
- EMD Serono Canada Gives Canadians a Deeper Look into Life with Multiple Sclerosis (MS)
- Mavenclad (Cladribine Tablets) Safety Profile in Multiple Sclerosis (MS) Reaffirmed with u
- MAVENCLAD™ (cladribine tablets) Receives Positive CADTH Canadian Drug Expert Committee (CD
- 2019-04-22 A journey to parenthood: shedding light on fertility
- 2019-05-22 MS From the Inside Out Virtual Reality Experience Comes to Montreal for One Day
- 2019-12-10 EMD Serono and the pCPA Complete Negotiations for MAVENCLAD
- 2020-02-06 Positive Recommendation for MAVENCLAD® (cladribine tablets) from INESSS
- 2020-09-29 Canadian Nurse Practitioner, Margaret Prociuk, Receives International Nighting
- 2020-10-27 MAVENCLAD® available through public drug plans for most eligible Canadians
- 2021-01-06 EMD Serono Appoints Manuel Zafra as New Managing Director for Canada
- 2021-01-11 Health Canada Approves BAVENCIO for Maintenance of Advanced Bladder Cancer
- 2021-04-06 National Caregiver Day 2021
- 2021-04-28 Data Stengthens Evidence for Use of MAVENCLAD During the COVID-19 Pandemic
- 2021-04-29 Bavencio Receives Reimbursement Recommendation for Maintenance Treatment of Advanced Bladder Cancer
- 2022-04-19 Increase in Cancer Caregivers in Canada
- 2022-10-18 Bladder Cancer Canada, EMD Serono and Pfizer Canada announce grant recipients
- 2023-06-15 EMD Serono launches Caregivers Concierge: An online resource hub for caregivers
- Subscribe to Media Releases
- Unsubscribe from Mailing List
- Media Contacts